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Efficacy of duplex ultrasound surveillance after
infrainguinal vein bypass may be enhanced by
identification of characteristics predictive of
graft stenosis development
Chelsey N. Tinder, MD, Joe P. Chavanpun, MD, Dennis F. Bandyk, MD, Paul A. Armstrong, DO,
Martin R. Back, MD, Brad L. Johnson, MD, and Murray L. Shames, MD, Tampa, Fla
Objective: Controversy regarding the efficacy of duplex ultrasound surveillance after infrainguinal vein bypass led to an
analysis of patient and bypass graft characteristics predictive for development of graft stenosis and a decision of secondary
intervention.
Methods: Retrospective analysis of a contemporary, consecutive series of 353 clinically successful infrainguinal vein
bypasses performed in 329 patients for critical (n  284; 80%) or noncritical (n  69; 20%) limb ischemia enrolled in a
surveillance program to identify and repair duplex-detected graft stenosis. Variables correlated with graft stenosis and
bypass repair included: procedure indication, conduit type (saphenous vs nonsaphenous vein; reversed vs nonreversed
orientation), prior bypass graft failure, postoperative ankle-brachial index (ABI) < 0.85, and interpretation of the first
duplex surveillance study as “normal” or “abnormal” based on peak systolic velocity (PSV) and velocity ratio (Vr) criteria.
Results: Overall, 126 (36%) of the 353 infrainguinal bypasses had 174 secondary interventions (endovascular, 100;
surgery, 74) based on duplex surveillance; resulting in 3-year Kaplan-Meier primary (46%), assisted-primary (80%), and
secondary (81%) patency rates. Characteristics predictive of duplex-detected stenosis leading to intervention (PSV:
443  94 cm/s; Vr: 8.6  9) were: “abnormal” initial duplex testing indicating moderate (PSV: 180-300 cm/s, Vr:
2-3.5) stenosis (P< .0001), non-single segment saphenous vein conduit (P< .01), warfarin drug therapy (P< .01), and
redo bypass grafting (P < .001). Procedure indication, postoperative ABI level, statin drug therapy, and vein conduit
orientation were not predictive of graft revision. The natural history of 141 (40%) bypasses with an abnormal first duplex
scan differed from “normal” grafts by more frequent (51% vs 24%, P < .001) and earlier (7 months vs 11 months) graft
revision for severe stenosis and a lower 3-year assisted primary patency (68% vs 87%; P < .001). In 52 (15%) limbs, the
bypass graft failed and 20 (6%) limbs required amputation.
Conclusions: The efficacy of duplex surveillance after infrainguinal vein bypass may be enhanced by modifying testing
protocols, eg, rigorous surveillance for “higher risk” bypasses, based on the initial duplex scan results and other
characteristics (warfarin therapy, non- single segment saphenous vein conduit, redo bypass) predictive for stenosis
development. (J Vasc Surg 2008;48:613-8.)The purpose of a surveillance program after infraingui-
nal bypass grafting is to identify stenotic or aneurysmal
lesions as they develop and repair them to prevent graft
thrombosis. When successful, functional bypass graft pa-
tency as measured by assisted primary patency rate is in-
creased, the need for redo bypass grafting reduced, and
limb salvage in the critical limb ischemia (CLI) population
prolonged. How to best perform graft surveillance remains
an unresolved issue. Duplex ultrasound imaging after in-
frainguinal vein bypass was not recommended in the recent
2007 Inter-Society Consensus for the Management of Pe-
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doi:10.1016/j.jvs.2008.04.053ripheral Arterial Disease (TASC II) document based pri-
marily on the results of a European multicenter random-
ized clinical trial.1,2 Instead a clinical surveillance program
(palpation of limb pulses, measurement of ankle-brachial sys-
tolic pressure index) was proposed beginning in the postop-
erative period and conducted every 6 months for a least 2
years. Our vascular group have been proponents of routine
duplex ultrasound surveillance based on outcome data dem-
onstrating asymptomatic development of duplex-detected
graft stenosis in one-quarter of patients, graft failure when
stenotic lesions were not repaired, and assisted primary pa-
tency rates 80% at 3 to 5 years.3-5 It was our intent in this
report to address this discrepancy in clinical practice guidelines
for surveillance after infrainguinal vein bypass.
Despite improvements in surgical technique and med-
ical therapy for atherosclerosis, vein bypass grafts continue
to fail; an outcome of severe consequence in the CLI
patient. Observations from a large multicenter trial of pa-
tients with CLI who underwent lower limb bypass with
excised autogenous vein found vein diameter and conduit
type were dominant determinants of early and late graft
failure, and suggested “aggressive postoperative graft sur-
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of the vein bypass is limited by the development of intralu-
minal stenosis and failure correlates with specific risk fac-
tors, it seems reasonable that application of duplex surveil-
lance should be individualized to the patient and graft type,
ie, a more rigorous protocol for “high-risk” vein bypasses.
We sought in this retrospective analysis to identify specific
patient and bypass graft characteristics, which are predictive
for the development of graft stenosis and the need for
secondary intervention with the intent to enhance the
efficacy of a graft surveillance program.
METHODS
Patient demographic data. From December 1999 to
August 2007, 353 consecutive infrainguinal vein bypasses
were performed in 329 patients to treat critical limb isch-
emia (n 284, 80%), disabling claudication (n 52, 15%),
or superficial femoral/popliteal aneurysm (n  17, 5%),
Table I. All bypasses were patent at the time of hospital
discharge with clinical examination indicating a successful
limb revascularization. In 114 (32%) of 353 limbs, the vein
bypass was performed as a redo procedure because of a
failed femorodistal arterial bypass. Measurement of ankle-
brachial systolic pressure index (ABI) was not possible in
17% of limbs due to tibial artery calcific disease and ankle
cuff incompressibility. Prior to bypass grafting, the patients’
medical treatment for peripheral arterial disease included
antiplatelet (78%) and statin (34%) drug therapy.
Infrainguinal vein bypass procedure. The vein graft-
ing technique varied with the surgeon’s preference, vein
availability, and the sites selected for the proximal and distal
anastomosis (Table II). Two hundred thirty-four (66%) of
the infrainguinal arterial bypasses were constructed with in
situ (n  61) or nonreversed, translocated (n  173)
saphenous vein bypass techniques. Valve lysis was per-
formed by direct valve cusp excision, Karmody scissors, or
with theMills (American V.Mueller, Chicago Ill) and Gore
(W. L. Gore & Associates, Flagstaff, Ariz) valvulotome.
The remaining 119 bypasses consisted of reversed great
saphenous vein (n  50), upper extremity cephalic or
Table I. Patient demographic data
Characteristic
Percent
of patients
Men 61%
Hypertension 78%
Coronary artery disease (prior CABG or PTA) 43%
Diabetes mellitus 53%
Incompressible tibial arteries 17%
History of smoking 75%
Current tobacco smoking 36%
End-stage renal disease 6%
Statin drug therapy 34%
Antiplatelet therapy 78%
CABG, coronary artery bypass grafting; PTA, percutaneous transluminal
angioplasty.basilic arm veins (n  35), or spliced arm and saphenousvein (n  34) conduits. Inflow artery of the infrainguinal
bypass included: common femoral artery (n  312, 89%),
superficial femoral artery (n  7), popliteal artery (n  35,
9%), and tibio-peroneal artery trunk (n  1).
The infrainguinal bypass was evaluated with color du-
plex ultrasound scanning after restoration of flow and ver-
ification of a functioning bypass by visual inspection and
pulse palpation. The previously described technique of
papavarine-augmented duplex testing was utilized to iden-
tify residual stenosis in the graft or anastomotic regions.7 At
the sites of duplex-detected stenosis, measurements of peak
systolic velocity (PSV) were made and the peak systolic
velocity ratio (Vr) was calculated, where Vr  PSV at
lesion/PSV proximal to the lesion. Graft and anastomotic
abnormalities with PSV  300 cm/s were revised as were
some graft sites with a PSV  180-200 cm/s if the Vr was
2-3 and color or power Doppler imaging demonstrated
50% lumen diameter reduction.
In absence of patient-specific contraindications, peri-
operative administration of antiplatelet therapy (aspirin,
clopidogrel), dextran-40 (25 mL/hour for 24 hours)
was routinely used. Approximately one third of the patients
(n  116) were discharged with warfarin sodium therapy
with an international normalization ratio target value of 1.5 to
2 unless specific indications for therapeutic anticoagulation
(international normalization ratio, 2-3.5) existed, such as
atrial fibrillation, mechanical heart valve, known hypercoagu-
lable condition, repeat vein bypass, or graft velocity less than
45 cm/sec. All patients were discharged on either antiplatelet
therapy alone or in combination with warfarin sodium ther-
apy.
Postoperative duplex ultrasound surveillance protocol.
All patients were enrolled in an outpatient surveillance
program, which included clinical assessment (interval his-
tory for limb ischemia, physical examination) of arterial
limb circulation, measurement of Doppler-derived ankle
systolic pressure (ankle-brachial index, ABI; normal
0.85), and color duplex scanning. Testing was performed
in an Intersocietal Commission for Accreditation of Vascu-
lar Laboratories-accredited vascular laboratory within 1
month of the procedure, at 3 to 4 months after the proce-
dure, and every 6 months thereafter. The interval between
duplex scans was reduced to 6 to 8 weeks in selected
Table II. Anatomic configuration of 353 infrainguinal
vein bypasses
Bypass, configuration No. of grafts
Femoropopliteal, above knee 46
Femoropopliteal, below knee 98
Femoral, anterior tibial 43
Femoral, posterior tibial 49
Femoral, peroneal 62
Femoral, tibioperoneal trunk 11
Femoral, pedal 9
Popliteal, tibial artery 25
Popliteal, pedal 10patients because of changes in the limb vascular status, or to
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sion. At each surveillance visit, the entire vein bypass graft
was scanned, including adjacent inflow and distal native
arteries. Criteria for “abnormal” first surveillance duplex
study was based on the final test interpretation indicating
presence of bypass graft lesion identified by color Doppler
imaging with associated increase in PSV (180 cm/s) and
Vr (2).When a graft stenosis was identified, measurement
of PSV and Vr were recorded with lesions having PSV 
300 cm/sec and Vr 3.5 considered for repair.5 If duplex
testing found recent (2 weeks) graft occlusion, or a
nonstenotic graft with low (PSV  45 cm/s) graft flow
velocity, angiography was recommended. The arterial by-
pass was also evaluated (real-time B-mode, color Doppler)
for aneurysmal degeneration with the criteria for vein an-
eurysm being a 2 times focal diameter increase and the
presence of mural thrombus.
Intervention to repair duplex scan-detected graft
stenosis or aneurysm. Graft lesions with duplex criteria
for repair were corrected by either open surgical or endo-
vascular (balloon dilation) intervention. Intervention type
was based on time from the original procedure, lesions
length, and vessel diameter with endovascular repair for
focal (2 cm) stenosis beyond 3 months of the grafting
procedure.5 Surgical intervention (vein patch angioplasty,
interposition graft, jump graft) was performed to repair
more extensive stenotic lesions, for residual stenosis after
angioplasty, and for aneurysmal degeneration. Intra-proce-
dural duplex scanning was performed after intervention to
verify a technically adequate repair using criteria of a non-
stenotic lumen on color Doppler imaging, PSV  180
cm/s, and Vr  2 at the repair site.
Data analysis. Outcome analysis was based on a ret-
rospective review of patient hospital, vascular clinic, and
vascular laboratory records. Patient outcomes including
death, graft thrombosis, graft revision, and amputation
were recorded throughout the follow-up interval that
ranged from a minimum of 3 to 96 months. Ten patients
were lost to follow-up beyond 6 months of the infraingui-
nal bypass procedure. Kaplan-Meier estimates of primary,
assisted-primary, and secondary graft patency, limb salvage,
and patient survival calculated according to the reporting
standards committee of the Society for Vascular Surgery.8
Comparisons between patency curves for different patient
groups were assessed by a log-rank statistic. Potential prog-
nostic factors associated with graft revision were evaluated
for categorical variables by using contingency table (2
analysis), with P value  .05 considered significant. Any
univariate association with a value of P .1 was included in
a binary logistic regression model using a forward stepwise
selection to identify variables associated with bypass graft
revision followed by block entry, binary logistic regression
to obtain estimates of P value. This retrospective study was
approved by our institutional review board.
RESULTS
Clinical patient follow-up (mean of 48 months) com-
bined with duplex ultrasound surveillance resulted in therevision of 126 (35%) of the 353 infrainguinal bypasses. A
total of 174 secondary interventions, including multiple
(two or more) revisions on 34 (10%) bypasses, were per-
formed. The 126 first graft revisions were performed to
repair duplex-detected stenosis (n  96), graft thrombosis
(n 28), graft entrapment (n 1), or vein graft aneurysm
(n 1). Themean (SD) values of PSV and VR of repaired
duplex-detected stenosis were 443 94 cm/s (range: 301
to 690 cm/s; median 436 cm/s) and 8.6  9 (range: 3 to
50; median: 6), respectively. Sites of revision included: vein
conduit (n  86), anastomotic region (n  38), and
inflow/outflow native artery (n 2). In 49 (38%) patients,
symptoms/signs of limb ischemia were present on clinical
examination. The majority (60%) of graft interventions
were performed using endovascular therapy (balloon an-
gioplasty, n  71; catheter-directed thrombolysis, n  3;
and atherectomy, n  1). The first graft revision of 51
bypasses was open surgical repair by redo bypass grafting
(n  22), ie, loss of secondary patency, vein-patch angio-
plasty (n 13), interposition/jump graft (n 12), throm-
bectomy (n  2), aneurysm repair (n  1), or graft
entrapment release (n  1). The graft surveillance pro-
gram produced 3-year (Kaplan-Meier estimates) primary,
assisted-primary, and secondary graft patency rates of 46%,
80% and 81%, respectively (Fig 1). There were no significant
differences at 3-year assisted-primary patency rates of bypasses
performed for CLI (78%) and non-CLI arterial disease (86%);
or for femoropopliteal (84%) vs infrageniculate (76%) vein
bypasses. In 52 (15%) limbs, the bypass graft failed and 20
(6%) limbs required below-knee amputations (19 amputa-
tions in the CLI patient group). Overall, limb salvage at 3
yearswas 90% (non-CLI: 98%;CLI: 88%). Patient survival was
79% at 3 years (non-CLI, 88%; CLI, 77%, P .03).
Characteristics predictive of graft stenosis (univariate
analysis) requiring intervention were: “abnormal” initial
duplex testing indicating moderate (PSV: 180-300 cm/s,
Vr: 2-3.5) stenosis (P  .0001), redo bypass grafting (P 
Fig 1. Kaplan-Meier estimates of primary, assisted-primary, and
secondary patency rates of 353 infrainguinal vein bypasses..001), non-single segment saphenous vein conduit (P 
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Gender, procedure indication (CLI or non-CLI disease),
presence of diabetes, postoperative ABI level, statin drug
therapy, saphenous vein conduit orientation (reversed vs
nonreversed or in situ), or bypass to an infrageniculate
target artery were not predictive of graft revision. After
successful bypass grafting, the initial ABI was0.85 in 51%
of the revascularized limbs with compressible tibial arteries,
and was associated with similar graft revision rate as limbs
with an ABI 0.85 or incompressible arteries. Multivariate
analysis confirmed a significant association between graft
revision and an abnormal first postoperative duplex scan
(P  .001; odds-ratio: 3.2, 2.02-5.1) and warfarin therapy
(P  .03; odds-ratio: 1.8, 1.08-2.89), but the variable
of “redo” bypass grafting did not predict revision status
(P  .07).
The natural history of the 141 (40%) bypasses with an
“abnormal” first duplex scan differed from grafts with
normal duplex ultrasound imaging by more frequent (52%
vs 25%, P.001) and earlier (7 months vs 11months) graft
revision, primarily for duplex-detected graft stenosis, and
lower 3-year primary patency (28% vs 62%, P .0001), Fig
2, A. This bypass cohort required a total of 101 secondary
interventions (47 open repairs, 54 endovascular); two times
the intervention rate compared with bypasses with normal
first duplex testing (0.7 vs 0.3 interventions per graft).
Time to first secondary intervention was less for bypasses
with abnormal first duplex scan (66% within 6 months)
compared with normal duplex scan bypasses (28% within 6
months), Fig 3. Despite secondary intervention(s) and
Table III. Univariate (contingency table) analysis of
potential factors associated with infrainguinal bypass graft
revision
Variable
Revision
(n  126)
No
revision
(n  227)
P
value
Gender (female) 46 (37%) 137 (60%) .57
Hypertension 97 (77%) 177 (78%) .89
Coronary artery disease 47 (37%) 80 (35%) .73
Diabetes mellitus 62 (49%) 124 (55%) .37
Smoking history 100 (79%) 165 (73%) .2
Non-critical limb ischemia 23 (18%) 46 (21%) .68
Critical limb ischemia 103 (82%) 181 (80%) .68
Infrageniculate bypass 80 (63%) 126 (56%) .18
Prior failed ipsilateral bypass 57 (45%) 57 (25%) .001a
Non single-segment
saphenous vein 34 (27%) 35 (15%) .01a
Nonreversed or in situ
saphenous vein 75 (60%) 159 (70%) .61
Abnormal postoperative
ABI (0.85) 68 (54%) 105 (46%) .26
Abnormal first duplex scan 73 (56%) 68 (30%) .0001a
Statin drug therapy 47 (37%) 153 (67%) .41
Antiplatelet drug therapy 96 (76%) 193 (76%) .37
Warfarin drug therapy 54 (43%) 62 (27%) .01a
ABI, ankle-brachial index.
aStatistical significant difference.similar duplex surveillance, the graft characteristic of anabnormal first duplex scan was associated with a lower
3-year assisted-primary patency (65% vs 84%; log-rank, P 
.001), Fig 2,A. The likelihood of graft failure was also higher
(P  .0001) in grafts with abnormal (35 [25%] of 141)
compared with normal (17 [8%] of 212) first duplex scans;
3-year secondary graft patency: 68% vs 86%, respectively.
The use of single-segment great saphenous vein con-
duit was associated with a higher 3-year primary patency
(49% vs 34%, P  .02), but assisted primary (82% vs 72%,
P .24) and secondary (83% vs 75%, P .35) patency rates
were similar to non-single segment saphenous vein (arm
vein, spliced vein) bypasses. Warfarin drug therapy was
more frequently prescribed to patients with CLI (36%),
prior failed bypass (45%), and nonsaphenous vein conduits
(50%), and correlated with a higher graft revision rate and
equally important a lower assisted primary (68% vs 86%,
P  .001) and secondary (72% vs 87%) graft patency. The
patient cohort with the “best” outcome after infrainguinal
bypass were the 178 patients, ie, approximately one-half of
the study population, who underwent single-segment sa-
phenous vein bypass and their initial duplex surveillance
documented no graft abnormality: 24% graft revision rate,
88% assisted primary graft patency, and 91% secondary
Fig 2. Kaplan-Meier estimates of primary (A) and assisted-pri-
mary (B) patency of 141 bypasses with abnormal first duplex scan
and 212 bypasses with normal first duplex scan.patency at 3 years.
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Infrainguinal vein bypass, a technically demanding proce-
dure especially in the CLI population, requires a revascular-
ization strategy with regard to conduit selection and bypass
configuration coupled with postoperative surveillance to
achieve long-term patency. Recent large-scale clinical trials
have confirmedmyointimal graft stenosis is the primary failure
mode of this procedure but its detection by duplex ultrasound
surveillance and repair may not guarantee success.2,6 In fact
the value of duplex surveillance has been questioned, deemed
not to be cost-effective or “worth the effort”, and with “limb
loss likely to occur irrespective of the surveillance strategy”.1-3
Our study addressed this clinical pessimism by identifying
several characteristics (initial duplex scan findings, prior failed
ipsilateral bypass, non-single segment saphenous vein con-
duit) that were highly predictive of graft stenosis develop-
ment. The majority of duplex-detected lesions identified dur-
ing surveillance were asymptomatic, progressed in severity on
serial scans permitting timely repair, and were amenable to
endovascular repair. Our surveillance strategy yielded assisted
primary graft patency rates at 3 years of 78% for CLI (limb
salvage rate of 88%) and 86% for non-CLI (claudication,
aneurysm) arterial disease, but at the cost of revising 35% of
the bypasses. The majority of graft revisions occurred within
12 months of the bypass grafting procedure. Our data clearly
demonstrates there is a role for duplex surveillance, but also an
opportunity to stratify grafts based on their risk for stenosis
development and applying more rigorous duplex surveillance
to only the “higher-risk” bypasses. Of note, characteristics
such as female gender, presence of diabetes, saphenous vein
grafting technique, or bypass to an infrageniculate target
artery did not predict a higher graft revision rate. We did not
address small vein diameter or bypass length as these charac-
teristics have been previously shown to correlate with infrain-
Fig 3. The number of secondary interventions performed during
eachpostoperative time interval onbypasseswith normal (n212) or
abnormal (n 141) first duplex surveillance scan. During the fol-
low-up period, 53 (25%) of 212 “normal” bypasses and 73 (52%) of
141 “abnormal” bypasses based on the first duplex scan were revised.guinal vein bypass failure.6The correlation of early graft flow disturbances identified
by duplex scanning with subsequent development of graft
stenosis requiring repair has been previously reported.9-11
These “residual” graft abnormalities have a different natural
history from “de novo” stenosis with higher likelihood to
progress to a severe stenosis, and graft thrombosis rate.12
Our review demonstrated 40% of the bypasses had an
abnormality identified on the first duplex surveillance scan
consisting primarily of a region of elevated PSV and lumen
reduction. This characteristic was highly predictive of sub-
sequent graft revision at 3 years primary patency of 64% if
normal vs 28% if abnormal; and was identified more fre-
quently than clinical series composed primarily of single-
segment reversed saphenous vein bypass (25% incidence
using similar duplex criteria).11 Despite intraoperative as-
sessment with color duplex ultrasound, graft abnormalities
consistent with a moderate stenosis were identified during
the early postoperative period, especially in the arm/spliced
vein bypass group. Using defined, objective “threshold”
duplex criteria (PSV  300 cm/s, Vr  3.5) for recom-
mending and performing graft stenosis repair, the revision
rate of bypasses with abnormal first duplex scan was two
times higher, typically required within 6 months of the
grafting procedure (66% of revisions), and resulted in a
lower assisted primary patency at 3 years (65% vs 84%).
Bypasses that failed typically required open surgical repairs
andmultiple re-interventions. These data indicate existence
of infrainguinal vein bypass cohort that exhibits a different
biologic behavior by a propensity toward myointimal ste-
nosis. Since at present, there is no effective medical therapy
to prevent myointimal graft stenosis, we believe the duplex
surveillance remains the best strategy to maximize long-term
graft patency. The patient cohort on oral warfarin anticoagu-
lation therapy required more graft revisions due to increased
characteristics of prior failed bypass grafts, CLI indication, and
non-single segment saphenous vein conduit usage.
In the 2007 Inter-Society Consensus for the Manage-
ment of Peripheral Arterial Disease (TASC II) document, a
clinical surveillance program (recommendation 42) was
suggested beginning in the immediate postoperative period
and conducted every 6 months thereafter for at least 2
years.1 Duplex ultrasound imaging was not recommended
in favor of a surveillance program consisting an interval
history for new limb symptoms of ischemia, palpation graft
and limb pulses, and measurement of resting, and if possi-
ble, postexercise ABIs. This surveillance strategy would
have not detected the majority of graft lesions repaired in
our patients including: the asymptomatic duplex-detected
stenosis in limbs with abnormal ABIs, limbs with incom-
pressible tibial arteries, and inadequate secondary interven-
tion for graft stenosis. Additionally, the use of exercise
testing in the CLI patient is often not possible especially in
the early (6 months) postoperative period. Our experience
and that of other vascular groups with expertise in vascular
laboratory testing support the routine use of duplex ultra-
sound after infrainguinal vein bypass.4-6,11-15 All patients
should be evaluated using duplex ultrasound within several
weeks of successful bypass grafting to identify residual graft
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saphenous vein bypass, redo bypass, un-controlled atheroscle-
rotic risk factors (tobacco abuse) have repeat graft imaging 3
to 4months later after graft arterialization andwound healing
has occurred. Other clinical trials have found bypass grafting
for CLI, vein diameter3 mm, and graft lengths50 cm to
be “risk-factors” for graft failure and associated with a two-
time increase in the number re-interventions within 1 year of
bypass grafting.6 Since graft stenosis development occurs pri-
marily within the first 12 to 18 months after bypass grafting,
duplex surveillance is most important during this time period.
Beyond 18months, the infrainguinal vein bypass with a “nor-
mal” duplex scan should have an annual evaluation of bypass
function (duplex testing andABImeasurement) testingwhich
reassures the patients and their physician(s) that arterial disease
progression has not occurred.When duplex surveillance iden-
tifies a “failing” vein bypass, the information provided by
high-resolutionB-mode and color/powerDoppler imaging is
valuable to the vascular specialist because the necessary ther-
apy (endovascular versus open surgical repair) to repair the
duplex-detected stenosis, aneurysm, or graft entrapment can
be based on the ultrasound findings alone.
Since the goal of infrainguinal bypass surveillance is to
prolong patency and avoid thrombotic events, the measure
of its success is the “assisted -primary patency rate”. Once
graft thrombosis occurs, secondary intervention to restore
patency is generally not successful or durable and this
principle was reflected in this study and other publications
of lower limb vein bypass outcomes by reporting a second-
ary patency which was not significantly higher than the
assisted primary patency rate. A significant difference be-
tween assisted primary and secondary patency indicates the
surveillance protocol did not adequately detect lesions that
led to thrombosis, but secondary procedures were success-
ful; outcome that has been observed in prosthetic graft
surveillance.14 Duplex surveillance should increase the
number of secondary interventions compared with clinical
assessments alone; thus primary patency will be less, and
should be significantly less than assisted-primary patency if
clinically significant lesions are identified and successfully
repaired. These outcome measures were observed in our
patients, eg, a significant (.0001) increase in assisted
primary patency compared with primary patency, but no
further improvement in secondary patency. Achieving an
assisted primary graft patency of 80% or greater at 3 years,
and 90% or greater limb salvage are also an important
measures of a successful surveillance program. When pri-
mary, assisted primary and secondary patency curves are not
significant, it can be concluded that surveillance is of no
benefit. This can occur because of inadequate surveillance,
failure to successfully repair identified grafts lesions in a
timely manner, or a result of poor compliance with the
surveillance protocol. Some vascular groups have con-
cluded duplex surveillance is too expensive or the logistics
to conduct a quality surveillance program are not available.
We disagree with this position. Based on duplex ultrasound
surveillance studies performed in 1980s, 1990s, 2000s, and
as reported herein, all of which demonstrated 80% orgreater assisted primary patency rates at 3 to 5 years, we
recommend duplex surveillance as a essential component of
patient care following infrainguinal vein bypass.3,5,10,13-15
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